Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Direct answer: Employer plans often deny semaglutide for weight loss because many employers choose not to include anti-obesity drugs as a benefit
Men with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use semaglutide
This observation aligns with emerging research in humans exploring how GLP-1 medications may influence brain pathways related to reward and consumption behaviors, such as alcohol consumption
Compounded medications are not FDA-approved as finished products
In contrast, subcutaneous injection is more likely to result in benign, malignant, and indeterminate tumors (including cystic and polypoid forms) of the thyroid such as medullary thyroid carcinoma, thyroid nodules, follicular thyroid carcinoma, and neck masses
Ongoing support and monitoring is included in Beyond Stem Cells programs
